Thursday, November 12, 2026

EUR/CHF Bearish Momentum: 0.809% Down In The Last 24 Hours

EUR/CHF Bearish Momentum: 0.809% Down In The Last 24 Hours

(VIANEWS) - EUR/CHF (EURCHF) has been up by 0.8091% for the last session's close. At 13:06 EST on Thursday, 1 August, EUR/CHF (EURCHF) is $0.94.

EUR/CHF (EURCHF) Range

Concerning EUR/CHF's daily highs and lows, it's 0.747% down from its trailing 24 hours low of $0.95 and 0.841% down from its trailing 24 hours high of $0.95.

EUR/CHF's yearly highs and lows, it's 4.408% up from its 52-week low and 5.055% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.18%, a negative 0.07%, and a positive 0.26%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.34% (last week), 0.26% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Eur/usd price analysis: oscillates in a range above 100-day SMA ahead of German CPI. According to FXStreet on Tuesday, 30 July, "Moreover, oscillators on the daily chart have started gaining negative traction, suggesting that the path of least resistance for the EUR/USD pair is to the downside. ", "A sustained strength beyond the latter could lift the EUR/USD pair above the 1.0865 horizontal barrier, towards the 1.0885-1.0890 region. "
  • Eur/usd price analysis: holds below 1.0850, the path of least resistance is to the downside. According to FXStreet on Wednesday, 31 July, "The EUR/USD pair trades on a stronger note around 1.0825, snapping the two-day losing streak during the Asian session on Wednesday. ", " Technically, the bearish outlook for EUR/USD remains in play as the major pair holds below the key 100-period Exponential Moving Average (EMA) on the 4-hour chart. "
  • Eur/usd jitters after fed rate hold, FOMC press conference in view. According to FXStreet on Wednesday, 31 July, "Price action is grinding into the midrange as daily candlesticks find technical support from the 200-day EMA at 1.0798, but momentum remains bearish as EUR/USD grinds down from the last swing high just above 1.0940."
  • Eur/usd cycles familiar levels as NFP jobs dump looms ahead. According to FXStreet on Wednesday, 31 July, "Fiber bids are hung up on the 50-day Exponential Moving Average (EMA) at 1.0818, and middling price action has EUR/USD grinding into a fresh technical middle just north of the 200-day EMA at 1.0796."
  • According to FXStreet on Thursday, 1 August, "That pricing seems far too aggressive in our view and instead, we think two-year EUR swap differentials will narrow further and provide EUR/USD with a little support.", "It therefore looks like EUR/USD can stay supported in a 1.0790-1.0850 range for the time being, andits best hope will be some much softer than expected US data."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com